2011 | 18F-fluorodeoxyglucose uptake on positron emission tomography as a prognostic predictor in locally advanced hepatocellular carcinoma.
| CANCER |
2011 | A randomized phase 2 study of docetaxel and S-1 versus docetaxel and cisplatin in advanced gastric cancer with an evaluation of SPARC expression for personalized therapy
| CANCER |
2023 | A randomized Phase 2 study to compare erlotinib with or without bevacizumab in previously untreated patients with advanced non-small cell lung cancer with EGFR mutation
| CANCER |
2007 | Adenosine Tiphosphate-based Chemotherapy Response Assay (ATP-CRA)-guided platinum-based 2-drug chemotherapy for unresectable nonsmall-cell lung cancer
| CANCER |
2001 | Adjuvant 5-fluorouracil plus doxorubicin in D2-3 resected gastric carcinoma: 15-year experience at a single institute. | CANCER |
2005 | Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma
| CANCER |
2014 | Clinical Outcome According to the Level of Preexisting Epidermal Growth Factor Receptor T790M Mutation in Patients With Lung Cancer Harboring Sensitive Epidermal Growth Factor Receptor Mutations | CANCER |
2017 | Clinical trial of nintedanib in patients with recurrent or metastatic salivary gland cancer of the head and neck: A multicenter phase 2 study (Korean Cancer Study Group HN14-01) | CANCER |
1997 | Correlation between K-ras gene mutation and prognosis of patients with nonsmall cell lung carcinoma | CANCER |
2012 | Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement
| CANCER |
2011 | DNA methylation predicts recurrence from resected stage III proximal colon cancer
| CANCER |
2016 | Efficacy and safety of dovitinib in pretreated patients with advanced squamous non-small cell lung cancer with FGFR1 amplification: A single-arm, phase 2 study | CANCER |
2023 | Efficacy and safety of pembrolizumab monotherapy in patients with advanced thyroid cancer in the phase 2 KEYNOTE-158 study | CANCER |
2010 | Frequent central nervous system failure after clinical benefit with epidermal growth factor receptor tyrosine kinase inhibitors in Korean patients with nonsmall-cell lung cancer.
| CANCER |
1997 | High Level of Urokinase-Type Plasminogen Activator Is a New Prognostic Marker in Patients with Gastric Carcinoma | CANCER |
2007 | Identical epidermal growth factor receptor mutations in adenocarcinomatous and squamous cell carcinomatous components of adenosquamous carcinoma of the lung
| CANCER |
2012 | Identification of novel immunogenic human leukocyte antigen-A 2402-binding epitopes of human papillomavirus type 16 E7 for immunotherapy against human cervical cancer. | CANCER |
2013 | Metastatic non–clear cell renal cell carcinoma treated with targeted therapy agents: Characterization of survival outcome and application of the International mRCC Database Consortium criteria | CANCER |
2021 | Olmutinib in T790M-positive non-small cell lung cancer after failure of first-line epidermal growth factor receptor-tyrosine kinase inhibitor therapy: A global, phase 2 study | CANCER |
2006 | Oncogenic T-antigen of JC virus is present frequently in human gastric cancers
| CANCER |
2014 | Patient-Reported Outcomes From EMILIA, a Randomized Phase 3 Study of Trastuzumab Emtansine (T-DM1) Versus Capecitabine and Lapatinib in Human Epidermal Growth Factor Receptor 2-Positive Locally Advanced or Metastatic Breast Cancer | CANCER |
2020 | Phase 2 study of afatinib among patients with recurrent and/or metastatic esophageal squamous cell carcinoma | CANCER |
2015 | Phase 2 study of dovitinib in patients with metastatic or unresectable adenoid cystic carcinoma | CANCER |
2012 | Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma
| CANCER |
2007 | Phase II trial of irinotecan and cisplatin with early concurrent radiotherapy in limited-disease small-cell lung cancer
| CANCER |
2008 | Pilot clinical trial of localized concurrent chemoradiation therapy for locally advanced hepatocellular carcinoma with portal vein thrombosis.
| CANCER |
2009 | Promoter methylation of the Wnt/beta-catenin signaling antagonist Dkk-3 is associated with poor survival in gastric cancer.
| CANCER |
2007 | Repetitive short-course hepatic arterial infusion chemotherapy with high-dose 5-fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma
| CANCER |
2016 | Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium | CANCER |
2018 | Risk factors for hepatocellular carcinoma by age, sex, and liver disorder status: A prospective cohort study in Korea. | CANCER |
2001 | The significance of granzyme B expression in patients with angiocentric lymphoma of the head and neck | CANCER |